Alzheimers and Dementia


There has been much in the way of research in these two areas. Recently I attended a conference in Toronto called BioFinance which brings together companies looking to receive funding (either private or public) and investors. At the conference I saw a company presentation from Transition Therapeutics that discussed its new Alzheimer’s drug called AZD-103 which just received fast-track status from the FDA on April 3, 2007. It has some pretty exciting pre-clinical data … it demonstrates a breakdown of amyloid fibrils within plaques that form on and within the brain essentially reversing damage. The positive results were shown in mice using a Morris water maze test (bottom of page). Could this be that miracle drug we’re all looking for?

Next, I want to discuss a study released which claims that lost memories could be restored by ‘rewiring’ brain; the study was done by MIT researcher Li-Huei Tsai and interestingly enough also utilized the Morris water maze test to show clinical efficacy of their therapy. Their team targeted HDACs (enzymes that prevent histone acetylation) with an HDAC inhibitor under the assumption that HDAC inhibitors initiate the rewiring of neurons. Of course its too early to tell if their therapy is going to go anywhere … let’s wait to see a licensing deal come out of their technology – then I’ll get excited.